Inveniam
VC Fund
Barcelona, Spain
Inveniam is a transaction and strategy advisory firm, with a strong focus in technology-based deals in Life Sciences and Resource Sustainability. Inveniam’s vision is to bridge the gap between technology originators and the market.Either serving the buy or the sell-side, Inveniam accompanies the client throughout the deal life cycle with a widearray of services, from opportunity scouting and assessment, all the way to commercialization, deal structuring and closing.Leveraging a diversified team across expertise and background, Inveniam offers a unique combination of skills and industry insight to support institutions, investors, start-ups and corporations with truly specialized advisory services. Inveniam is headquartered in Spain and Israel, and has an outstanding world reach through its alliances and collaborators. Together we ignite traction to your technology venture.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Inveniam invests in
Stages Inveniam invests in
Countries Inveniam invests in
Round sizes
Round size
- Seed
- $568k–$1.1M
Investment Focus
Industry
- Biopharma 1 (25%)
- Health Care 1 (25%)
- Life Science 1 (25%)
- Therapeutics 1 (25%)
- Biotechnology 1 (25%)
Stage
- Seed 2 (50%)
- Grant 1 (25%)
- Funding Round 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NIMBLE Diagnostics
|
NIMBLE Diagnostics is a technological organization that develops and provides services related to biotechnology research activities. | $1.1M / Jan 19, 2023 | |
|
NIMBLE Diagnostics
|
NIMBLE Diagnostics is a technological organization that develops and provides services related to biotechnology research activities. | $1.1M / Grant / Jan 15, 2023 | |
|
NIMBLE Diagnostics
|
NIMBLE Diagnostics is a technological organization that develops and provides services related to biotechnology research activities. | $1.1M / Seed / Jan 15, 2023 | |
AtG Therapeutics
|
AtG is a spin-off company from the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO) in Barcelona that specialized in the discovery and development of new therapeutic techniques for cancer resistance to improve the lives of cancer patients. | $568.3K / Seed / Jul 21, 2022 |
Co-Investors
Grow Venture Partners
3 deals together
Namarel Ventures
2 deals together
Blue Goose Capital
1 deal together
WA4STEAM
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Inveniam invest in?
Inveniam invests primarily in Biopharma, Health Care and Life Science startups, most often at Seed and Grant stage. Most of the 4 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Inveniam's check size?
Inveniam typically joins rounds of $568k–$1.1M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Inveniam participates in.
When did Inveniam last invest?
The most recent investment recorded for Inveniam closed in Jan 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
